Complete Response to Anti-Pd-1 Antibody Monotherapy in Metastatic Melanoma-Can Therapy Be Discontinued? A Review of Current Literature

Journal of Cancer Biology and Therapeutics
doi 10.18314/gjct.v5i1.1543
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Gratis Open Access Publishers LLC

Related search

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2017English

Complete Response to Anti-Pd-L1 Antibody in a Metastatic Bladder Cancer Associated With Novel MSH4 Mutation and Microsatellite Instability

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Retinal Vasculitis and Ocular Vitreous Metastasis Following Complete Response to PD-1 Inhibition in a Patient With Metastatic Cutaneous Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Blood Monocyte Frequency May Be a Biomarker for Response to Anti–PD-1

Cancer Discovery
Oncology
2018English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Journal of the American Academy of Dermatology
Dermatology
2016English

Evaluation of Clinicopathological Factors in PD-1 Response: Derivation and Validation of a Prediction Scale for Response to PD-1 Monotherapy

British Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy